Yuankai Shi
Baohui Han
Wei Li
Ping Yu
Yunpeng Liu
Cuimin Ding
Xia Song
Ma Zhi Yong
Xinling Ren
Ji Feng Feng
Helong Zhang
Gongyan Chen
Ning Wu
Xiaohong Han
Chen Yao
Yong Song
Shucai Zhang
Lieming Ding
Fenlai Tan
Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Shanghai Renji Hospital, Shanghai, China
First Hospital Affiliated to Jilin University, Jilin, China
Department of Lung Cancer Medical Oncology, Sichuan Cancer Hospital, Chengdu, China
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
Tumor Hospital Of Hebei Province, Shijiazhuang, China
Shanxi Provincial Tumor Hospital, Taiyuan, China
Henan Cancer Hospital, Zhengzhou, China
Xijing Hospital, Xian, China
China Jinagsu Province Inst of Cancer Rsrch, Jiangsu, China
Xijing Hospital, The Fourth Military Medical University, Xi'an, China
The Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilong Jiang Province, China
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
Peking University Clinical Research Institute, Beijing, China
Nanjing Military General Hospital, Nanjing, China
Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
Betta Pharmaceuticals Co, Ltd, Hangzhou, China
The 1st Affiliated Hospital, Hangzhou, China
China
Betta Pharmaceutical
Oncology (ONC)
Lung Cancer
Epidermal growth factor receptor
Cisplatin
Pemetrexed
Icotinib
Positive
Randomized
Open Label
III
NCT01719536
N/A
Final